Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions

2013329 citationsJournal Articlehybrid Open Access

Authors

Michael D. Dake · Stanford Medicine

Gary M. Ansel · Riverside Methodist Hospital

Michael R. Jaff · Massachusetts General Hospital

Takao Ohki · The Jikei University Hospital

Richard R. Saxon · Tri-City Medical Center

H. Bob Smouse · St. Francis Medical Center

S.A. Snyder ·

Abstract

Two-year outcomes with the paclitaxel-eluting stent support its sustained safety and effectiveness in patients with femoropopliteal artery disease, including the long-term superiority of the DES to PTA and to provisional BMS placement. (Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery; NCT00120406; Zilver(®) PTX™ Global Registry; NCT01094678).

Topics & Keywords

Peripheral Artery Disease Management Coronary Interventions and Diagnostics Vascular Procedures and Complications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the American College of Cardiology

Volume 61, Issue 24, pp. 2417-2427

DOI: 10.1016/j.jacc.2013.03.034

Field-Weighted Citation Impact: 47.32